Login / Register
![]()
{{userInfo.last_name}} {{userInfo.first_name}}
Cart({{cartNumber}})
TACTUS
Latine
- Anglicus
- Gallus
- Germanus
- Portuguese
- Spanish
- Russian
- Iaponica
- Coreanica
- Arabic
- Hibernica
- Graeculus
- Turkish
- Italiae
- DANICULUS
- Romanian
- Indonesiaca
- Bohemica
- Africikaans
- SCELIDUS
- POLICULO
- Basque
- Catalana
- Esperanto
- Hindi
- Lago
- Illyrica
- Amharicus
- Armeniana
- Azerbaieni
- Belarusian
- Bengalica
- BOSNIAN
- Bulgarica
- Cebuano
- Chichewa
- Corsican
- Crovatica
- Batavica
- Estonian
- Philippinica
- Fennica
- Frisian
- Gallaeca
- Georgian
- Gujarati
- Haitiaian
- Hausa
- HAWAIUS
- Hebraica
- Hmong
- Hungarian
- IMETIANICUS
- Igbo
- Javanese
- Cannada
- Kazakh
- Khmer
- Kurdica
- Kyrgyz
- Latine
- Latvian
- Lithuanian
- Lithuanian
- Macedonian
- MALAGASUS
- Malae
- Malayalam
- Melitensis
- Maorice
- Marathi
- Mongolica
- Burmese
- Nepalica
- Norwegian
- Pastua
- Persicus
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Moravica
- Carnica
- Somali
- Samoan
- Scoti Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ucraina
- Urdu
- Uzbek
- Vietnamica
- Cambrica
- Xhosa
- LOKINDIS
- Yoruba
- Zuluensis
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Nuntium
MMXXV - V - XXX - Pfizer et reddere Sinis scriptor 3sbio $ 1.25 billion sursum fronte ad accedere a cancer medicamento quod operatur similiter ad immunotherapy ex Akooo et culmen.
Pfizer emit in PD - I / Vegf competition cum 3SBIO paciscor
MMXXV - V - XXX - Quod Advisory Committee dixit Vaccine makers ut scissor eorum cursus doses ad "jn.1" coronavirus ludge. FDA non sequi consilium sed plerumque.
FDA panel commendat observatio Covidi offa targeted ad idem contentionem ut annum
MMXXV - V - XXX - Quod Biotech mos utor cash ad Fund Humanum Testing of a medicamento crediderit habere potentia in pluribus autoimmune conditionibus.
Glycoera suscitat $ 130m, equitantes Interdum in dapibus Degraders
MMXXV - V - XXIX - Vaccines per mRNA technology sunt studied pro decennia, peritorum dicere.
Quid scimus de salute, efficaciam MRNA Vaccines inter recens scrutinio
